A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the drug galcanezumab is safe and effective in
participants with episodic migraine. The study will last about 53 weeks and may include up to
12 visits.